Data Sheet (Cat.No.T2507)

TargetMol

Azeliragon

Chemical Properties



CAS No. :	603148-36-3
Formula:	C32H38ClN3O2
Molecular Weight:	532.12
Storage:	Store at low temperature Powder: -20°C for 3 years | In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.

Biological Description

Description	Azeliragon (TTP488) is an antagonist at the Receptor for Advanced Glycation End products; is evaluated as a potential treatment for patients with mild-to-moderate Alzheimer_acute_s disease (AD).
Targets(IC50)	Beta Amyloid,Advanced Glycation End Products
Kinase Assay	Recombinant Kinase Assays [1]: The ability of AZD5438 to inhibit cdk activity is examined using a scintillation proximity assay with recombinant cdk-cyclin complexes of cyclin-Ecdk2, cdk2-cyclin A, cdk4-cyclin D, and recombinant retinoblastoma substrate (amino acids 792-928) or cdk1-cyclin B1 with a peptide substrate derived from the in vitro p34cdc2 phosphorylation site of histone H1 (biotin-X-Pro-Lys-Thr-Pro-Lys-Lys-Ala-Lys-Lys-Leu). The activity of AZD5438 against recombinant cdk5/p25 (at 2 μM ATP) is determined in a scintillation proximity assay-based assay using peptide substrate (AKKPKTPKKAKKLOH). Inhibition of glycogen synthase kinase 3β activity is determined with scintillation proximity assay based on the use of human purified glycogen synthase kinase 3βenzyme and eukaryotic initiation factor 2B substrate (at 1 μM ATP). AZD5438 is screened against active recombinant human cdk6-cyclin D3, cdk7-cyclin H/MAT1 (cdk activating kinase complex), and cdk9-cyclin T using the kinase selectivity screening service.

Solubility Information

Solubility	DMSO: 11 mg/mL (20.67 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.76 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.8793 mL	9.3964 mL	18.7928 mL
5 mM	0.3759 mL	1.8793 mL	3.7586 mL
10 mM	0.1879 mL	0.9396 mL	1.8793 mL
50 mM	0.0376 mL	0.1879 mL	0.3759 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Burstein AH, et al. BMC Neurol. 2014 Jan 15;14:12.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481